Extended drug treatment for life threatening infections

Hospital patients who develop infections where 10% of sufferers die will be offered double the traditional course of antibiotics in a new trial. 

Patients with serious abdominal infections are usually given a two-week course, but often this is unsuccessful. Now, researchers at the University of Leeds and the University of York are trialling a month-long course to establish whether it is more effective at clearing up the infection. 

The EXTEND trial is funded by the National Institute for Health and Care Research (NIHR) and is co-led by Dr Andrew Kirby, Associate Professor at the University of Leeds’ School of Medicine and an NHS Consultant in Microbiology, and Mr Dermot Burke, Associate Professor in Surgery in Leeds’ School of Medicine. 

Dr Kirby said: “There can be aversion to prescribing longer courses of antibiotics due to the risk of antimicrobial resistance to the drugs. But these infections are extremely serious and the current treatments do not work for a large proportion of patients. We want to see if a longer, fixed course cures more people – whether it stops the infection coming back, prevents new infections, and saves lives. 

Serious abdominal infections happen when the intestine is damaged, usually by bowel surgery or a disease, causing bacteria living in the intestine to leak into the surrounding cavity. These infections are a leading cause sepsis in patients on intensive care units. Sepsis in the UK kills more people than breast, bowel and prostate cancer combined.  

Long courses of antibiotics can be contentious because they may increase the risk of bacteria finding ways to survive the antibiotics, meaning the antibiotics no longer work to fight the infection. Also, there is guidance that four days of antibiotics may be enough to treat serious abdominal infections. 

The problem with short antibiotic courses is that 20% of patients are not cured and 10% die following their infection. 

Currently, doctors rely on blood tests and patient-reported symptoms to assess whether the infection has cleared up.  But if the bacteria have not been fully eradicated by the antibiotics, they can start to regrow, resulting in a recurrence of the infection and potentially more episodes of sepsis. This is why researchers now want to establish whether a set 28-day course of antibiotics can cure these infections more effectively than a doctor deciding when to stop the course.  

Mr Burke said: “Intra-abdominal infections make patients feel miserable, weary and keep people in hospital for lengthy periods. Improved methods of treatment are greatly needed.” 

Professor Andrew Ustianowski, NIHR Joint National Infection Specialty Lead, said: “Intra-abdominal infections and sepsis are very serious issues in our populations. We have a variety of antibiotics that can help but we need specific research to inform us on how best to use them, including for how long.  

 “This NIHR-funded study is therefore an important trial that I expect will have a direct beneficial impact on our future management of these infections.” 

The EXTEND trial is due to start in August 2022 and will run for three years. It will follow patients for six months. Half will receive a course of antibiotics prescribed by their doctor, normally for a week or two, and the other half will receive the 28-day course. The trial will be open to patients in hospital with a serious abdominal infection. 

Further information 

Contact University of Leeds press officer Lauren Ballinger via l.ballinger@leeds.ac.uk with media enquiries. 

Visit the EXTEND trial webpage for further details. 

University of Leeds  

The University of Leeds is one of the largest higher education institutions in the UK, with more than 38,000 students from more than 150 different countries. We are renowned globally for the quality of our teaching and research.  

We are a values-driven university, and we harness our expertise in research and education to help shape a better future for humanity, working through collaboration to tackle inequalities, achieve societal impact and drive change.   

The University is a member of the Russell Group of research-intensive universities, and plays a significant role in the Turing, Rosalind Franklin and Royce Institutes. www.leeds.ac.uk   

Follow University of Leeds or tag us in to coverage: Twitter | Facebook | LinkedIn | Instagram 

The National Institute for Health and Care Research (NIHR) 

The NIHR is the nation’s largest funder of health and care research. The NIHR: 

  1. Funds, supports and delivers high quality research that benefits the NHS, public health and social care 

  1. Engages and involves patients, carers and the public in order to improve the reach, quality and impact of research 

  1. Attracts, trains and supports the best researchers to tackle the complex health and care challenges of the future 

  1. Invests in world-class infrastructure and a skilled delivery workforce to translate discoveries into improved treatments and services 

  1. Partners with other public funders, charities and industry to maximise the value of research to patients and the economy 

The NIHR was established in 2006 to improve the health and wealth of the nation through research, and is funded by the Department of Health and Social Care. In addition to its national role, the NIHR supports applied health research for the direct and primary benefit of people in low- and middle-income countries, using UK aid from the UK government. 

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.

#Extended #drug #treatment #life #threatening #infections

Leave a Comment

Your email address will not be published.